Boston Scientific Shows Off No Deaths and Low PVL Rates in Small Lotus TAVR Study
Boston Scientific this week presented new data from the Respond extension study of its Lotus transcatheter aortic valve replacement with its Depth Guard technology, touting no deaths and low rates of paravalvular regurgitation.
Data from the study was presented at the Cardiovascular Research Technologies CRT 2017 annual meeting in Washington D.C.
The 50-patient Respond Extension study aimed to assess clinical and device performance outcomes with its Lotus Valve in combination with the Depth Guard technology.
Data from the study was presented at the Cardiovascular Research Technologies CRT 2017 annual meeting in Washington D.C.
The 50-patient Respond Extension study aimed to assess clinical and device performance outcomes with its Lotus Valve in combination with the Depth Guard technology.